The global breast cancer drugs market is estimated to grow at a CAGR of around 10.0% during the forecast period. Rising prevalence of breast cancer coupled with the emergence of novel therapies, improving healthcare infrastructure across emerging economies, and rising health awareness among patients are some of the driving factors for the market growth. Breast cancer is a tumor or lymph of tightened mass/flesh which may have cyst filled. It occurs in the breast tissues that are made up of glands for production of milk called lobules, or the duct connecting lobules to the nipple. At the initial stage, there is a discharge of pus and white fluid from the nipple and the affected breast has hard lymph that can be physically examined wherein some cases, little pain can be experienced. The painless lump is one of the most common physical signs. Breast cancer is sometimes spread to underarm lymph nodes causing a lump or swelling, even before the original breast tumor becomes large enough to be felt. According to the Breastcancer.org, in 2018, around 266,120 new cases of invasive breast cancer and around 63,960 new cases of non-invasive breast cancer were estimated to be diagnosed among women of the US. 

Segmental Outlook  

The global breast cancer drugs market is segmented on the basis of drug class type and geography. On the basis of the drug class type, the market is classified into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. Immunotherapy segment is estimated to dominate the global colorectal cancer drugs market over the forecast period. When compared with chemotherapeutic, immunotherapeutic tend to have lesser adverse effects. Whereas, complications associated with the chemotherapeutic such as non-specificity, toxic side effects, and development of resistance is likely to hinder the growth of chemotherapeutic segment and encourage the adoption of other drug class types treatment. 

Global Breast Cancer Drugs Market Share by Drug Class Type, 2018 (%)

Regional Outlook 

Geographically, the study of the global breast cancer drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (Germany, UK, Italy, France, Italy, Spain, and Rest of Europe), and Rest of the World (RoW). Over the forecast period, the global market is expected to be dominated by North America due to increasing breast cancer patients across major economies of the region such as the US and Canada. Moreover, increased people awareness, presence of key market players coupled with their increased focus on the development of breast cancer solutions, and well-developed healthcare infrastructure are some of the pivotal growth factors for the regional market growth.

Global Breast Cancer Drugs Market Growth, by Region 2019-2025

Europe is estimated to contribute considerable market share

Rising prevalence of breast cancer is one of the primary factors that is augmenting the demand for novel therapies for breast cancer including drugs. Breast cancer is the most common cancer in UK. According to the National Statistics, UK, during 2016, a huge number of cancer incidences were registered such as breast cancer, prostate cancer, and lung cancer. There were around 45,656 numbers of cases of breast cancer that were registered in females and around 304 cases were registered for males. Moreover, cancer is one of the fatal diseases which have a high prevalence in Germany. In 2018, as per the World Health Organization, nearly 608,000 cases related to cancer were registered in the country. Cases related to breast cancer were maximum in 2018 with an incidence rate of 85.4 per 100,000. Further, a significant market for breast cancer drugs is also expected in France due to prevalence of disease. France has the 3rd highest rate of breast cancer among European Union members. There has been an improvement in the technology in breast cancer detection technology including improvements in current techniques and new detection strategies aimed at finding distinctive molecular signatures of a pre-malignant or malignant breast tumor. This is expected to provide sufficient thrust for the growth of the regional market in the near future. 

Market Players Outlook

Additionally, the market is characterized by the presence of several market players that are engaged in the development and marketing of novel therapies for the treatment of breast cancer. Some of the key players operating in the global breast cancer drugs market include AbbVie Inc., AstraZeneca PLC, Celgene Corp., F. Hoffmann-La Roche ltd., Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, and several others. In order to remain competitive in the market, these market players adopt various strategies such as mergers and acquisitions, product offering expansion, geographical expansion, partnerships and collaborations, and others. Players operating in the market are also focusing on the market opportunities to capture the market share. 

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Breast Cancer Drugs market. Based on the availability of data, information related to products and services, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.